

# Richard A Larson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1997019/publications.pdf>

Version: 2024-02-01

544  
papers

76,842  
citations

813  
118  
h-index

540  
265  
g-index

566  
all docs

566  
docs citations

566  
times ranked

35948  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib vs conventional care in older patients with late-stage mutant- <i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	1.4	27
2	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	7.2	42
3	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	6.3	9
4	Follow-up of patients with R/R <i>FLT3</i> -mutation-“positive” AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
5	Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. <i>Pediatric Blood and Cancer</i> , 2022, , e29613.	1.5	1
6	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3433-3439.	5.2	5
7	Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. <i>Blood Advances</i> , 2022, 6, 3812-3820.	5.2	9
8	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. <i>Blood Advances</i> , 2022, 6, 5345-5355.	5.2	24
9	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. <i>Journal of Clinical Oncology</i> , 2022, 40, 3709-3718.	1.6	9
10	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814
11	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.	5.2	10
12	High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. <i>Blood Advances</i> , 2022, 6, 5570-5581.	5.2	8
13	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	1.4	805
14	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	7.1	51
15	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
16	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	7.2	159
17	Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021, , 93-104.	0.2	1
18	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2220-2231.	7.2	20

#	ARTICLE	IF	CITATIONS
19	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. <i>Blood Cancer Journal</i> , 2021, 11, 39.	6.2	22
20	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
21	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
22	Economics influences therapy decisions in chronic myeloid leukaemia: should it?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3693-3698.	2.5	1
23	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.	1.0	4
24	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	1.4	91
25	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
26	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	5.2	15
27	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. <i>Blood Advances</i> , 2021, 5, 4140-4148.	5.2	6
28	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , 2021, 5, 4691-4700.	5.2	9
29	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. <i>European Journal of Cancer</i> , 2021, 157, 428-440.	2.8	26
30	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
31	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021, 111, 106736.	0.8	3
32	Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification. <i>Hematologic Malignancies</i> , 2021, , 157-167.	0.2	0
33	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. <i>Blood</i> , 2021, 138, 337-337.	1.4	0
34	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2021, 138, 221-221.	1.4	2
35	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
36	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). <i>Blood</i> , 2021, 138, 226-226.	1.4	0

#	ARTICLE	IF	CITATIONS
37	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). Blood, 2021, 138, 3369-3369.	1.4	0
38	Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2021, 138, 1746-1746.	1.4	9
39	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). Journal of Geriatric Oncology, 2020, 11, 107-113.	1.0	38
40	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34
41	Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2020, 55, 2204-2206.	2.4	5
42	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplantation, 2020, 55, 1161-1168.	2.4	11
43	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncology Practice, 2020, 16, e464-e475.	2.9	12
44	Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. Journal of Geriatric Oncology, 2020, 11, 1199-1209.	1.0	8
45	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
46	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advances, 2020, 4, 696-705.	5.2	44
47	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	5.2	9
48	Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Acute Lymphoblastic Leukemia (B-ALL). Blood, 2020, 136, 7-8.	1.4	15
49	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. Blood, 2020, 136, 41-42.	1.4	2
50	Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only. Blood, 2020, 136, 25-26.	1.4	0
51	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2020, 136, 39-40.	1.4	0
52	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 629-638.	1.3	4
53	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer, 2019, 125, 4181-4192.	4.1	61
54	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. Best Practice and Research in Clinical Haematology, 2019, 32, 101102.	1.7	6

#	ARTICLE	IF	CITATIONS
55	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	27.0	796
56	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
57	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	7.2	76
58	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Experimental Hematology and Oncology, 2019, 8, 1.	5.0	21
59	Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leukemia Research, 2019, 80, 40-42.	0.8	4
60	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	5.2	11
61	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Advances, 2019, 3, 3488-3498.	5.2	62
62	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	5.2	34
63	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatric Blood and Cancer, 2019, 66, e27542.	1.5	14
64	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood, 2019, 133, 1548-1559.	1.4	292
65	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. Blood, 2019, 134, 4176-4176.	1.4	3
66	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 1956-1956.	1.4	2
67	Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication. Blood, 2019, 134, 475-475.	1.4	3
68	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. Blood, 2019, 134, 261-261.	1.4	5
69	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. Blood, 2019, 134, 2924-2924.	1.4	22
70	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	1.4	0
71	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. Blood, 2019, 134, 705-705.	1.4	3
72	Allo-HSCT in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab vs Standard-of-Care Chemotherapy From a Randomized Phase 3 Study. Biology of Blood and Marrow Transplantation, 2018, 24, S105-S106.	2.0	0

#	ARTICLE	IF	CITATIONS
73	Pepsi® or Coke®? Influence of acid on dasatinib absorption. Journal of Oncology Pharmacy Practice, 2018, 24, 156-158.	0.9	13
74	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
75	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer, 2018, 18, 359.	2.6	15
76	Therapy-Related Acute Promyelocytic Leukemia. , 2018, , 231-242.		0
77	RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nature Communications, 2018, 9, 1163.	12.8	132
78	Managing CNS disease in adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 3-13.	1.3	59
79	Treatment of Acute Promyelocytic Leukemia in Adults. Journal of Oncology Practice, 2018, 14, 649-657.	2.5	44
80	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
81	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Advances, 2018, 2, 444-453.	5.2	115
82	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances, 2018, 2, 1705-1718.	5.2	16
83	Imatinib is still recommended for frontline therapy for CML. Blood Advances, 2018, 2, 3648-3652.	5.2	15
84	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Advances, 2018, 2, 1522-1531.	5.2	33
85	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances, 2018, 2, 3608-3617.	5.2	39
86	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 4.	17.0	52
87	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Experimental Hematology and Oncology, 2018, 7, 1.	5.0	24
88	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). Blood, 2018, 132, 2800-2800.	1.4	6
89	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). Blood, 2018, 132, 1534-1534.	1.4	1
90	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). Blood, 2018, 132, 435-435.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	1.4	18
92	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). Blood, 2018, 132, 1386-1386.	1.4	4
93	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Blood, 2018, 132, 1739-1739.	1.4	2
94	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	1.4	0
95	Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. Blood, 2018, 132, 5843-5843.	1.4	0
96	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	1.4	0
97	Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics Journal, 2017, 17, 274-279.	2.0	35
98	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2127-2133.	1.3	20
99	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 2017, 376, 917-927.	27.0	926
100	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	1.4	78
101	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. British Journal of Haematology, 2017, 178, 906-913.	2.5	41
102	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&2 study. Lancet Oncology, The, 2017, 18, 1061-1075.	10.7	402
103	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine, 2017, 377, 454-464.	27.0	1,628
104	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	1.4	4,375
105	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase. Cancer Cell, 2017, 31, 127-141.	16.8	1,139
106	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017, 102, 519-528.	3.5	22
107	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia, 2017, 31, 34-39.	7.2	67
108	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 2017, 1, 331-340.	5.2	57



#	ARTICLE	IF	CITATIONS
109	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four <scp>CALGB</scp> (alliance) clinical trials. American Journal of Hematology, 2016, 91, 199-204.	4.1	44
110	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	7.2	99
111	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	3.5	30
112	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
113	Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematologica, 2016, 136, 210-218.	1.4	15
114	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. Hematologic Malignancies, 2016, , 231-255.	0.2	0
115	miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nature Communications, 2016, 7, 11452.	12.8	113
116	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer, 2016, 122, 304-311.	4.1	129
117	Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer, 2016, 122, 2178-2185.	4.1	70
118	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Research, 2016, 76, 4470-4480.	0.9	48
119	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1065-1072.	2.0	20
120	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia and Lymphoma, 2016, 57, 1807-1813.	1.3	9
121	Positron Emission Tomography-Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. Journal of Clinical Oncology, 2016, 34, e123-e125.	1.6	1
122	Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. Journal of Clinical Oncology, 2016, 34, e46-e48.	1.6	9
123	Clinical impact of <i>ABL1</i> kinase domain mutations and <i>IKZF1</i> deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia and Lymphoma, 2016, 57, 2298-2306.	1.3	45
124	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 2016, 30, 1044-1054.	7.2	685
125	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003.	6.3	82
126	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. Blood, 2016, 128, 214-214.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase. Blood, 2016, 128, 2706-2706.	1.4	5
128	WT1 Peptide Vaccine Is Able to Induce WT1-Specific Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. Blood, 2016, 128, 3984-3984.	1.4	1
129	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 901-901.	1.4	42
130	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. Journal of Clinical Oncology, 2016, 34, e18537-e18537.	1.6	0
131	Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality. Blood, 2016, 128, 5844-5844.	1.4	1
132	Is there a best TKI for chronic phase CML?. Hematology American Society of Hematology Education Program, 2015, 2015, 250-256.	2.5	5
133	Overexpression and knockout of miR-126 both promote leukemogenesis. Blood, 2015, 126, 2005-2015.	1.4	65
134	Is there a best TKI for chronic phase CML?. Blood, 2015, 126, 2370-2375.	1.4	42
135	Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of <scp>CALGB</scp> (Alliance) 10301, a multicentre phase <scp>II</scp> study. British Journal of Haematology, 2015, 171, 373-377.	2.5	10
136	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leukemia and Lymphoma, 2015, 56, 3031-3037.	1.3	9
137	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2015, 16, 57-66.	10.7	1,031
138	A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs, 2015, 33, 371-379.	2.6	8
139	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128
140	Final results of EFC6663: A multicenter, international, phase 2 study of alvociclib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research, 2015, 39, 495-500.	0.8	46
141	Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 443-449.	0.4	31
142	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Annals of Hematology, 2015, 94, 249-257.	1.8	39
143	Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia, 2015, 29, 2113-2116.	7.2	37
144	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology, 2015, 33, 4167-4175.	1.6	149

#	ARTICLE	IF	CITATIONS
145	miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. <i>Leukemia</i> , 2015, 29, 1210-1213.	7.2	17
146	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 559-564.	2.0	58
147	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 567-575.	7.2	69
148	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. <i>Blood</i> , 2015, 126, 3784-3784.	1.4	2
149	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2518-2518.	1.4	3
150	Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3777-3777.	1.4	0
151	Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling. <i>Blood</i> , 2015, 126, 3667-3667.	1.4	1
152	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 927-938.	2.3	27
153	Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). <i>Haematologica</i> , 2014, 99, 111-115.	3.5	94
154	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. <i>Haematologica</i> , 2014, 99, 308-313.	3.5	32
155	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014, 55, 1523-1532.	1.3	55
156	The spectrum of somatic mutations in high-risk acute myeloid leukaemia with $\text{t}(7q)$ . <i>British Journal of Haematology</i> , 2014, 166, 550-556.	2.5	29
157	Imatinib 800Âmg daily induces deeper molecular responses than imatinib 400Âmg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 223-232.	2.5	56
158	Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. <i>Cancer</i> , 2014, 120, 1010-1017.	4.1	25
159	Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1005-1013.	2.4	7
160	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , 2014, 38, 329-333.	0.8	21
161	The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. <i>Annals of the New York Academy of Sciences</i> , 2014, 1310, 7-31.	3.8	54
162	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. <i>British Journal of Haematology</i> , 2014, 165, 102-111.	2.5	78

#	ARTICLE	IF	CITATIONS
163	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
164	Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. <i>Clinical Cancer Research</i> , 2014, 20, 490-498.	7.0	99
165	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>British Journal of Haematology</i> , 2014, 165, 497-503.	2.5	38
166	Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. <i>Leukemia Research</i> , 2014, 38, 1091-1096.	0.8	17
167	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S39-S40.	2.0	3
168	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. <i>Haematologica</i> , 2014, 99, 1204-1211.	3.5	42
169	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. <i>Haematologica</i> , 2014, 99, 1373-1379.	3.5	213
170	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014, 123, 1353-1360.	1.4	231
171	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. <i>Blood</i> , 2014, 124, 1093-1093.	1.4	4
172	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. <i>Blood</i> , 2014, 124, 4541-4541.	1.4	42
173	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	1.4	6
174	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014, 124, 796-796.	1.4	83
175	Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2463-2463.	1.4	0
176	Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). <i>Blood</i> , 2014, 124, 2464-2464.	1.4	0
177	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. <i>Blood</i> , 2014, 124, 2509-2509.	1.4	2
178	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 90-98.	4.1	104
179	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2013, 48, 1437-1443.	2.4	18
180	Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1172-1181.	1.6	164

#	ARTICLE	IF	CITATIONS
181	Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome <sup>+</sup> positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 1411-1413.	7.2	41
182	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. <i>Cancer</i> , 2013, 119, 4170-4179.	4.1	37
183	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. <i>Leukemia</i> , 2013, 27, 107-112.	7.2	212
184	The evolving challenge of therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 309-317.	1.7	71
185	Current Practices in the Management of Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 48-54.	0.4	9
186	Prediction of outcomes in patients with Ph <sup>+</sup> chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. <i>Leukemia</i> , 2013, 27, 907-913.	7.2	23
187	Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. <i>Leukemia and Lymphoma</i> , 2013, 54, 2654-2659.	1.3	9
188	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 1242-1249.	1.3	23
189	Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. <i>Journal of Clinical Oncology</i> , 2013, 31, 923-929.	1.6	96
190	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	1.4	1,743
191	A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). <i>Investigational New Drugs</i> , 2013, 31, 1311-1320.	2.6	21
192	The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). <i>Leukemia and Lymphoma</i> , 2013, 54, 252-254.	1.3	34
193	Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3.	0.4	2
194	miR-9 is an essential oncogenic microRNA specifically overexpressed in <i>mixed lineage leukemia</i> rearranged leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11511-11516.	7.1	97
195	Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies. <i>Journal of Clinical Oncology</i> , 2013, 31, 440-447.	1.6	56
196	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 4854-4860.	1.4	546
197	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013, 121, 3703-3708.	1.4	91
198	inv(16)/t(16;16) acute myeloid leukemia with non <sup>+</sup> type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. <i>Blood</i> , 2013, 121, 385-391.	1.4	39

#	ARTICLE	IF	CITATIONS
199	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548.	1.4	1
200	Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia, 2012, 26, 959-962.	7.2	84
201	Gemtuzumab Ozogamicin: Time to Resurrect?. Journal of Clinical Oncology, 2012, 30, 3921-3923.	1.6	95
202	Treatment-influenced associations of PML-RAR $\alpha$ mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood, 2012, 120, 2098-2108.	1.4	52
203	Cytogenetics, Not Just Previous Therapy, Determines the Course of Therapy-Related Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 2300-2302.	1.6	30
204	miR-495 is a tumor-suppressor microRNA down-regulated in <i>MLL</i>-rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19397-19402.	7.1	109
205	Amelanocytic Anhidrotic Alopecia Areata-like Phenotype After Allogeneic Hematopoietic Cell Transplant. Archives of Dermatology, 2012, 148, 931.	1.4	6
206	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 2012, 120, 3898-3905.	1.4	154
207	Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia. Cancer Cell, 2012, 22, 524-535.	16.8	154
208	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia and Lymphoma, 2012, 53, 445-450.	1.3	20
209	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood, 2012, 119, 2314-2324.	1.4	145
210	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 18-36.e6.	2.0	58
211	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 16-17.	2.0	18
212	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 913-921.	2.0	40
213	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 4515-4523.	1.6	363
214	A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology and Oncology, 2012, 5, 71.	17.0	56
215	Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy, 2012, 14, 707-715.	0.7	16
216	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 70, 345-350.	2.3	25



#	ARTICLE	IF	CITATIONS
217	Author reply to Fujimi et al. European Journal of Clinical Pharmacology, 2012, 68, 1573-1574.	1.9	0
218	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leukemia and Lymphoma, 2012, 53, 1743-1748.	1.3	16
219	The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia, 2012, 26, 1713-1717.	7.2	19
220	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood, 2012, 120, 249-258.	1.4	64
221	<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. Journal of Clinical Oncology, 2012, 30, 3109-3118.	1.6	242
222	Age-Related Prognostic Impact of Different Types of <i>DNMT3A</i> Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 742-750.	1.6	244
223	FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 662-667.	1.5	48
224	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 2012, 26, 2197-2203.	7.2	395
225	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2012, 30, 2483-2491.	1.6	120
226	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 2012, 68, 723-733.	1.9	86
227	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	1.4	17
228	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Blood, 2012, 120, 1686-1686.	1.4	12
229	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230.	1.4	14
230	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 3535-3535.	1.4	1
231	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood, 2012, 120, 44-44.	1.4	4
232	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. Blood, 2012, 120, 676-676.	1.4	2
233	Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. Translational Pediatrics, 2012, 1, 120-2.	1.2	9
234	Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia. Blood, 2012, 120, 3499-3499.	1.4	1



#	ARTICLE	IF	CITATIONS
235	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. <i>Blood</i> , 2011, 118, 6438-6445.	1.4	158
236	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1796-1803.	2.0	123
237	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <i>Lancet Oncology</i> , The, 2011, 12, 841-851.	10.7	444
238	TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1373-1381.	1.6	291
239	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011, 96, 1488-1495.	3.5	20
240	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	1.4	344
241	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 7007-7013.	1.4	73
242	Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. <i>Blood</i> , 2011, 118, 3525-3527.	1.4	49
243	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011, 118, 4188-4198.	1.4	52
244	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011, 118, 6920-6929.	1.4	246
245	CML: live long and prosper. <i>Blood</i> , 2011, 118, 4499-4500.	1.4	4
246	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2011, 38, 215-224.	2.2	21
247	Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?. <i>Seminars in Oncology</i> , 2011, 38, 196-214.	2.2	21
248	High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. <i>Leukemia Research</i> , 2011, 35, 329-333.	0.8	27
249	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355.	1.6	124
250	Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. <i>Leukemia</i> , 2011, 25, 800-807.	7.2	24
251	GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011019.	1.3	13
252	PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER "GOOD RISK" ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011032.	1.3	29

#	ARTICLE	IF	CITATIONS
253	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Blood, 2011, 118, 114-114.	1.4	2
254	Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML) – An International Study. Blood, 2011, 118, 2521-2521.	1.4	1
255	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. Blood, 2011, 118, 258-258.	1.4	7
256	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 2772-2772.	1.4	5
257	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. Blood, 2011, 118, 289-289.	1.4	8
258	Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only,. Blood, 2011, 118, 3522-3522.	1.4	1
259	Treatment of Acute Lymphoblastic Leukemia in Middle-Age and Older Adults. , 2011, , 115-126.		0
260	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. Blood, 2011, 118, 1948-1948.	1.4	0
261	Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. Blood, 2011, 118, 2541-2541.	1.4	3
262	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. Blood, 2011, 118, 830-830.	1.4	1
263	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. Blood, 2011, 118, 1791-1791.	1.4	0
264	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. Blood, 2011, 118, 236-236.	1.4	0
265	A Phase II Prospective Feasibility Study of Clofarabine Cyto-reduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	1.4	0
266	MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2011, 118, 1462-1462.	1.4	0
267	P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood, 2010, 116, 1413-1421.	1.4	113
268	Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 788-792.	1.4	80
269	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116, 3751-3757.	1.4	348
270	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010, 116, 3758-3765.	1.4	440

#	ARTICLE	IF	CITATIONS
271	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 3622-3626.	1.4	201
272	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010, 116, 2420-2428.	1.4	70
273	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010, 116, 5650-5659.	1.4	33
274	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963
275	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2251-2259.	27.0	1,497
276	Micro-RNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia. <i>Chemico-Biological Interactions</i> , 2010, 184, 21-25.	4.0	13
277	Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. <i>Chemico-Biological Interactions</i> , 2010, 184, 50-57.	4.0	80
278	Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Philadelphia-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. <i>American Journal of Hematology</i> , 2010, 85, 164-170.	4.1	80
279	Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. <i>Leukemia</i> , 2010, 24, 1299-1301.	7.2	97
280	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101. <i>Journal of Clinical Oncology</i> , 2010, 28, 4500-4506.	1.6	71
281	Prognostic Significance of Expression of a Single MicroRNA, <i>miR-181a</i> , in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5257-5264.	1.6	176
282	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	1.6	699
283	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. <i>Leukemia and Lymphoma</i> , 2010, 51, 2240-2249.	1.3	40
284	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. <i>Journal of Biological Chemistry</i> , 2010, 285, 32596-32605.	3.4	42
285	Therapy-related myeloid sarcoma with an <i>NPM1</i> mutation. <i>Leukemia and Lymphoma</i> , 2010, 51, 2130-2131.	1.3	4
286	Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010, 28, 437-444.	1.6	178
287	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 5660-5669.	1.4	110
288	Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 596-604.	1.6	305

#	ARTICLE	IF	CITATIONS
289	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 995-1006.	1.3	16
290	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010, 116, 2291-2291.	1.4	12
291	Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder. <i>Blood</i> , 2010, 116, 2709-2709.	1.4	7
292	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3472-3479.	1.6	181
293	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. <i>Leukemia and Lymphoma</i> , 2009, 50, 1809-1817.	1.3	50
294	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	1.4	414
295	Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. <i>Leukemia and Lymphoma</i> , 2009, 50, 1589-1596.	1.3	25
296	Prognostic Importance of <i>MN1</i> Transcript Levels, and Biologic Insights From <i>MN1</i> -Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3198-3204.	1.6	149
297	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan. <i>Cancer</i> , 2009, 115, 84-93.	4.1	6
298	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2009, 115, 551-560.	4.1	108
299	A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 859-864.	2.3	30
300	Auto-SCT for AML in second remission: CALGB Study 9620. <i>Bone Marrow Transplantation</i> , 2009, 44, 353-359.	2.4	30
301	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	1.6	1,188
302	Allogeneic Hematopoietic Cell Transplantation Is Not Recommended for all Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 11-16.	2.0	10
303	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. <i>Journal of Hematology and Oncology</i> , 2009, 2, 20.	17.0	48
304	Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. <i>Leukemia and Lymphoma</i> , 2009, 50, 868-870.	1.3	2
305	Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 85-91.	1.3	12
306	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. <i>Leukemia</i> , 2009, 23, 1054-1061.	7.2	808

#	ARTICLE	IF	CITATIONS
307	Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 601-608.	2.4	6
308	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. <i>Blood</i> , 2009, 113, 5575-5582.	1.4	93
309	High rates of durable response are achieved with imatinib after treatment with interferon $\alpha$ plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. <i>Haematologica</i> , 2009, 94, 1669-1675.	3.5	45
310	Therapy-related myeloid neoplasms. <i>Haematologica</i> , 2009, 94, 454-459.	3.5	71
311	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. <i>Blood</i> , 2009, 114, 1126-1126.	1.4	358
312	Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.. <i>Blood</i> , 2009, 114, 1579-1579.	1.4	2
313	Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 536-536.	1.4	24
314	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 790-790.	1.4	124
315	Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. <i>Investigational New Drugs</i> , 2008, 26, 233-239.	2.6	45
316	A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. <i>Investigational New Drugs</i> , 2008, 26, 331-338.	2.6	12
317	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. <i>Leukemia</i> , 2008, 22, 1200-1206.	7.2	341
318	Allogeneic hematopoietic cell transplantation for adults with ALL. <i>Bone Marrow Transplantation</i> , 2008, 42, S18-S24.	2.4	8
319	Therapy-Related Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 418-429.	2.2	272
320	Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1209-1216.	2.0	75
321	Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. <i>Blood</i> , 2008, 111, 4022-4028.	1.4	565
322	Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15535-15540.	7.1	418
323	Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 7095-7101.	7.0	67
324	Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008, 26, 4934-4939.	1.6	114



#	ARTICLE	IF	CITATIONS
325	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine, 2008, 358, 1919-1928.	27.0	427
326	Wilms's Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4595-4602.	1.6	230
327	Patients With Acute Myeloid Leukemia and <i>RAS</i> Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4603-4609.	1.6	138
328	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, <i>CEBPA</i> Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 5078-5087.	1.6	294
329	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia and Lymphoma, 2008, 49, 531-537.	1.3	11
330	Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia â€” Cancer and leukemia group B study 10107. Leukemia and Lymphoma, 2008, 49, 1274-1278.	1.3	12
331	What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood, 2008, 112, 1646-1654.	1.4	479
332	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111, 1834-1839.	1.4	284
333	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 2008, 111, 1552-1559.	1.4	243
334	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood, 2008, 111, 5371-5379.	1.4	174
335	MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112, 741-749.	1.4	90
336	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood, 2008, 112, 4193-4201.	1.4	357
337	Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B. , 2008, , 137-144.		4
338	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood, 2008, 112, 2809-2809.	1.4	18
339	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	1.4	1
340	Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.. Blood, 2008, 112, 3238-3238.	1.4	29
341	MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19971-19976.	7.1	435
342	Therapy-Related Myelodysplastic Syndrome. American Journal of Clinical Pathology, 2007, 127, 197-205.	0.7	96



#	ARTICLE	IF	CITATIONS
343	Etiology and Management of Therapy-Related Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2007, 2007, 453-459.	2.5	79
344	Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 829-832.	1.3	3
345	High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2007, 25, 3337-3343.	1.6	184
346	Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 2007, 25, 793-798.	1.6	371
347	End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood, 2007, 109, 1810-1816.	1.4	83
348	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood, 2007, 109, 5164-5167.	1.4	92
349	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, 110, 2309-2315.	1.4	349
350	Chronic Lymphocytic Leukemia Masquerading as Uveitis. Retina, 2007, 27, 1311-1312.	1.7	5
351	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood, 2007, 109, 5136-5142.	1.4	287
352	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 2007, 25, 799-804.	1.6	320
353	Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia and Lymphoma, 2007, 48, 1799-1805.	1.3	16
354	Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood, 2007, 109, 4164-4167.	1.4	173
355	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	1.4	352
356	Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. Best Practice and Research in Clinical Haematology, 2007, 20, 29-37.	1.7	72
357	Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2007, 40, 1027-1032.	2.4	74
358	Three New Drugs for Acute Lymphoblastic Leukemia: Nelarabine, Clofarabine, and Forodesine. Seminars in Oncology, 2007, 34, S13-S20.	2.2	31
359	Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients &lt; 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.. Blood, 2007, 110, 157-157.	1.4	22
360	IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Blood, 2007, 110, 25-25.	1.4	42

#	ARTICLE	IF	CITATIONS
361	Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.. Blood, 2007, 110, 2815-2815.	1.4	14
362	Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).. Blood, 2007, 110, 756-756.	1.4	9
363	Genomic Rearrangements Associated with -5/del(5q) and -7/del(7q) in Myeloid Leukemias.. Blood, 2007, 110, 1813-1813.	1.4	1
364	MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.. Blood, 2007, 110, 3181-3181.	1.4	0
365	Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. Journal of Clinical Oncology, 2006, 24, 437-443.	1.6	233
366	Management of Acute Lymphoblastic Leukemia in Older Patients. Seminars in Hematology, 2006, 43, 126-133.	3.4	53
367	Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opinion on Pharmacotherapy, 2006, 7, 1791-1799.	1.8	4
368	Myelodysplasia: When to treat and how. Best Practice and Research in Clinical Haematology, 2006, 19, 293-300.	1.7	12
369	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	1.4	1,184
370	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review. Biology of Blood and Marrow Transplantation, 2006, 12, 1-30.	2.0	109
371	Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 954-964.	2.0	122
372	Survival advantage from imatinib compared with the combination interferon- $\alpha$ plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 2006, 108, 1478-1484.	1.4	210
373	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood, 2006, 108, 63-73.	1.4	285
374	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood, 2006, 108, 1677-1683.	1.4	123
375	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology, 2006, 28, 1099.	3.3	10
376	Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation, 2006, 37, 307-310.	2.4	42
377	A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare "poor prognosis" myeloid malignancies. Leukemia, 2006, 20, 1295-1297.	7.2	109
378	Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemotherapy and Pharmacology, 2006, 57, 199-206.	2.3	26

#	ARTICLE	IF	CITATIONS
379	Phase III study of PSC-833 (valsopodar) in combination with vincristine, doxorubicin, and dexamethasone (valsopodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95). Cancer, 2006, 106, 830-838.	4.1	120
380	Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology, 2006, 24, 3895-3903.	1.6	541
381	Fifty Years of Clinical Research by the Leukemia Committee of the Cancer and Leukemia Group B. Clinical Cancer Research, 2006, 12, 3556s-3563s.	7.0	11
382	Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1030-1035.	7.1	32
383	Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2006, 24, 3904-3911.	1.6	618
384	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine, 2006, 355, 2408-2417.	27.0	3,212
385	CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.. Blood, 2006, 108, 2293-2293.	1.4	3
386	Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.. Blood, 2006, 108, 429-429.	1.4	9
387	Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.. Blood, 2006, 108, 797-797.	1.4	19
388	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1952-1952.	1.4	0
389	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	1.4	0
390	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology, 2006, 28, 1099-103.	3.3	10
391	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 2005, 105, 49-53.	1.4	376
392	Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood, 2005, 105, 3420-3427.	1.4	125
393	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Research, 2005, 29, 1253-1257.	0.8	95
394	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2005, 35, 965-970.	2.4	53
395	Therapy-related myeloid leukaemia: A model for leukemogenesis in humans. Chemico-Biological Interactions, 2005, 153-154, 187-195.	4.0	51
396	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 2005, 104, 1442-1452.	4.1	429

#	ARTICLE	IF	CITATIONS
397	Overexpression of the ETS-Related Gene, <i>ERG</i> , Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9234-9242.	1.6	226
398	Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 8089-8096.	7.0	23
399	Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805. <i>Clinical Cancer Research</i> , 2005, 11, 4176-4181.	7.0	124
400	Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 482-493.	1.6	119
401	Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5728-5738.	1.6	134
402	Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2711-2718.	1.8	13
403	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5705-5717.	1.6	324
404	Acute Lymphoblastic Leukemia: Older Patients and Newer Drugs. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 131-136.	2.5	30
405	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. <i>Journal of Clinical Oncology</i> , 2005, 23, 3404-3411.	1.6	143
406	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 823-861.	2.0	67
407	Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).. <i>Blood</i> , 2005, 106, 165-165.	1.4	4
408	Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. <i>Blood</i> , 2005, 106, 1833-1833.	1.4	5
409	Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005, 106, 1848-1848.	1.4	5
410	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. <i>Blood</i> , 2005, 106, 2022-2022.	1.4	1
411	Treatment Failure Is Strongly Predicted by P-Glycoprotein (Pgp) Function but Not by Multidrug Resistance Protein (MRP-1), Breast Cancer Resistance Protein (BCRP) or Lung Resistance Protein (LRP) in Acute Myeloid Leukemia (AML) Patients 60 Years and Older Receiving Intensive Chemotherapy (CALGB Tj ETQq1 1 <sup>14</sup> 0.784314 <sup>3</sup> rgBT /Ove	1.4	14
412	Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.. <i>Blood</i> , 2005, 106, 2524-2524.	1.4	3
413	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.. <i>Blood</i> , 2005, 106, 407-407.	1.4	19
414	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. <i>Blood</i> , 2005, 106, 1818-1818.	1.4	0

#	ARTICLE	IF	CITATIONS
415	Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621. <i>Journal of Clinical Oncology</i> , 2004, 22, 4290-4301.	1.6	145
416	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- $\alpha$ : A Cancer and Leukemia Group B study. <i>International Journal of Oncology</i> , 2004, 25, 143.	3.3	7
417	Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2004, 22, 4816-4822.	1.6	42
418	Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. <i>Journal of Clinical Oncology</i> , 2004, 22, 1087-1094.	1.6	190
419	Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. <i>Journal of Clinical Oncology</i> , 2004, 22, 2410-2418.	1.6	101
420	A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 553-561.	2.3	5
421	Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group AB. <i>British Journal of Haematology</i> , 2004, 124, 275-288.	2.5	78
422	RAS,FLT3, andTP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 217-223.	2.8	62
423	Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma. <i>Cancer</i> , 2004, 100, 1438-1448.	4.1	96
424	Adult de novo acute myeloid leukemia with t(6;11)(q27;q23). <i>Cancer</i> , 2004, 101, 1420-1427.	4.1	40
425	Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2004, 28, 537-540.	0.8	7
426	Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2004, 363, 535-536.	13.7	139
427	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. <i>Blood</i> , 2004, 103, 4373-4374.	1.4	6
428	Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. <i>Blood</i> , 2004, 104, 3520-3526.	1.4	89
429	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. <i>Blood</i> , 2004, 103, 4036-4042.	1.4	96
430	Therapy-related myeloid leukemia: stochastic or idiosyncratic?. <i>Blood</i> , 2004, 104, 602-603.	1.4	1
431	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. <i>Blood</i> , 2004, 104, 1145-1145.	1.4	11
432	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. <i>Blood</i> , 2004, 104, 2321-2321.	1.4	1



#	ARTICLE	IF	CITATIONS
433	The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 264-264.	1.4	10
434	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. Blood, 2004, 104, 873-873.	1.4	5
435	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. Blood, 2004, 104, 918-918.	1.4	2
436	Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.. Blood, 2004, 104, 3485-3485.	1.4	0
437	Is Family History of Breast Cancer Associated with Therapy-Related Myelodysplastic Syndrome and Therapy-Related Leukemia? .. Blood, 2004, 104, 2018-2018.	1.4	0
438	Polymorphisms in the MLL breakpoint cluster region (BCR). Human Genetics, 2003, 113, 80-91.	3.8	14
439	Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine. Cancer, 2003, 97, 1471-1480.	4.1	59
440	A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia, 2003, 17, 323-327.	7.2	46
441	Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. Leukemia, 2003, 17, 488-491.	7.2	11
442	Elitekâ„rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 2003, 17, 499-514.	7.2	79
443	Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia, 2003, 17, 691-699.	7.2	34
444	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research, 2003, 27, 1091-1096.	0.8	23
445	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003, 101, 6-14.	1.4	549
446	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 4642-4649.	1.6	2,425
447	Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood, 2003, 102, 43-52.	1.4	630
448	Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma, 2003, 44, 39-48.	1.3	17
449	Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study. Journal of Clinical Oncology, 2003, 21, 2138-2146.	1.6	191
450	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	27.0	3,227



#	ARTICLE	IF	CITATIONS
451	Progress and challenges in the therapy of adult acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2003, 10, 284-289.	2.5	13
452	Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. <i>Blood</i> , 2003, 102, 7-16.	1.4	56
453	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. <i>Blood</i> , 2003, 102, 1613-1618.	1.4	222
454	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003, 102, 2309-2310.	1.4	2
455	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002, 100, 4325-4336.	1.4	1,444
456	Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2441-2452.	1.6	377
457	Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3070-3075.	7.1	100
458	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. <i>International Journal of Oncology</i> , 2002, 21, 1041.	3.3	15
459	Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14925-14930.	7.1	138
460	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539.	1.4	1,096
461	Acute lymphoblastic leukaemia: diagnosis and classification. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 597-621.	1.7	52
462	Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2002, 20, 2429-2440.	1.6	1,735
463	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-1232.	1.4	335
464	Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2002, 20, 3878-3884.	1.6	167
465	t(1;3)(p36;p21) is a recurring therapy-related translocation. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 186-192.	2.8	16
466	Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 37-45.	2.3	62
467	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). <i>Leukemia</i> , 2002, 16, 1627-1636.	7.2	217
468	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-32.	1.4	105

#	ARTICLE	IF	CITATIONS
469	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002, 8, 2812-9.	7.0	40
470	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>International Journal of Oncology</i> , 2002, 21, 1041-51.	3.3	13
471	Transcript Map and Comparative Analysis of the 1.5-Mb Commonly Deleted Segment of Human 5q31 in Malignant Myeloid Diseases with a del(5q). <i>Genomics</i> , 2001, 71, 235-245.	2.9	90
472	Preliminary Experience with a New Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 297-307.	1.3	15
473	Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001, 19, 3611-3621.	1.6	139
474	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 3244-3254.	1.6	837
475	Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 2482-2492.	1.6	94
476	Rapid Presumptive Diagnosis of Hantavirus Cardiopulmonary Syndrome by Peripheral Blood Smear Review. <i>American Journal of Clinical Pathology</i> , 2001, 116, 665-672.	0.7	115
477	Poor prognosis acute myelogenous leukemia: 1- $\alpha$ response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). <i>Leukemia Research</i> , 2000, 24, 671-680.	0.8	6
478	Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013. <i>Journal of Clinical Oncology</i> , 2000, 18, 1301-1308.	1.6	58
479	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1750-1757.	27.0	939
480	Refinement of the Smallest Commonly Deleted Segment of Chromosome 20 in Malignant Myeloid Diseases and Development of a PAC-Based Physical and Transcription Map. <i>Genomics</i> , 2000, 67, 28-39.	2.9	41
481	Prevalence of the Inactivating 609C $\rightarrow$ T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. <i>Blood</i> , 1999, 94, 803-807.	1.4	264
482	Prevalence of the Inactivating 609C $\rightarrow$ T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. <i>Blood</i> , 1999, 94, 803-807.	1.4	9
483	High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: Treatment technique and related complications. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 391-396.	0.8	36
484	Myeloid Leukemia After Cytotoxic Therapy and Other Hematotoxins. <i>Hematology</i> , 1998, 3, 397-400.	1.5	0
485	CBFA2(AML1) Translocations With Novel Partner Chromosomes in Myeloid Leukemias: Association With Prior Therapy. <i>Blood</i> , 1998, 92, 2879-2885.	1.4	110
486	Metastatic Adenocarcinoma Arising in a Congenital Foregut Cyst of the Esophagus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 64-66.	1.3	52

#	ARTICLE	IF	CITATIONS
487	dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations ofTP53. Genes Chromosomes and Cancer, 1997, 20, 282-291.	2.8	58
488	Long-term follow-up of cancer and leukemia group B studies in acute myeloid leukemia. Cancer, 1997, 80, 2210-2214.	4.1	20
489	Long-term follow-up of cancer and leukemia group B studies in acute myeloid leukemia. Cancer, 1997, 80, 2210-2214.	4.1	5
490	THERAPY-RELATED MYELOID LEUKEMIA. Hematology/Oncology Clinics of North America, 1996, 10, 293-320.	2.2	143
491	Acute Myelomonocytic Leukemia with Abnormal Eosinophils Presenting as an Ovarian Mass: A Report of Two Cases and a Review of the Literature. Gynecologic Oncology, 1995, 56, 307-311.	1.4	24
492	Reimmunization after allogeneic bone marrow transplantation. American Journal of Medicine, 1995, 98, 389-398.	1.5	29
493	Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemotherapy and Pharmacology, 1995, 36, 204-210.	2.3	1
494	Phase I Trial of a Genetically Engineered Interleukin-2 Fusion Toxin (DAB <sub>486</sub> IL-2) as a 6 Hour Intravenous Infusion in Patients with Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 257-262.	1.3	22
495	Acute leukemia in adults: recent developments in diagnosis and treatment. Ca-A Cancer Journal for Clinicians, 1994, 44, 326-352.	329.8	39
496	Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. American Journal of Hematology, 1993, 42, 147-157.	4.1	13
497	Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. American Journal of Hematology, 1993, 42, 359-366.	4.1	10
498	Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study. American Journal of Hematology, 1993, 43, 286-290.	4.1	25
499	ACUTE MYELOID LEUKAEMIA FOLLOWING INTERFERON-ALFA TREATMENT OF HAIRY CELL LEUKAEMIA. British Journal of Haematology, 1993, 83, 519-520.	2.5	19
500	Effects of rhGM-CSF on Myeloid Clonogenic Cells in Acute Myelogenous Leukemia Patients. Leukemia and Lymphoma, 1993, 10, 183-186.	1.3	2
501	Listeriosis after 2-Chlorodeoxyadenosine Treatment. New England Journal of Medicine, 1993, 328, 813-814.	27.0	16
502	Rearrangement of the MLL Gene in Acute Lymphoblastic and Acute Myeloid Leukemias with 11q23 Chromosomal Translocations. New England Journal of Medicine, 1993, 329, 909-914.	27.0	491
503	A Pilot Study of Prophylactic Aerosolized Amphotericin B In Patients at Risk for Prolonged Neutropenia. Leukemia and Lymphoma, 1992, 8, 229-233.	1.3	50
504	c-myc and c-myb expression in acute myelogenous leukemia. Leukemia Research, 1992, 16, 1003-1011.	0.8	27

#	ARTICLE	IF	CITATIONS
505	The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study. British Journal of Haematology, 1992, 82, 337-346.	2.5	16
506	Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. Leukemia Research, 1991, 15, 51-57.	0.8	4
507	Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leukemia Research, 1991, 15, 773-780.	0.8	33
508	Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. British Journal of Haematology, 1991, 79, 33-39.	2.5	22
509	The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. British Journal of Haematology, 1991, 79, 390-397.	2.5	22
510	Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. Leukemia and Lymphoma, 1991, 4, 145-148.	1.3	1
511	Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes and Cancer, 1990, 2, 147-158.	2.8	103
512	Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer, 1990, 65, 2619-2623.	4.1	9
513	Deletions of Interferon Genes in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1990, 322, 77-82.	27.0	214
514	Relapse of Hodgkin's Disease After 14 Years of Complete Remission. Leukemia and Lymphoma, 1990, 3, 223-226.	1.3	4
515	Methyl Transferase Activity in Secondary Leukemia. , 1990, 53, 277-289.		0
516	Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1989, 216, 119-126.	0.4	12
517	HYPERSENSITIVITY REACTION TO HIGH-DOSE CYTARABINE. British Journal of Haematology, 1989, 73, 274-275.	2.5	19
518	der(5)t(5;7)(q11.2;p11.2): A new recurring abnormality in malignant myeloid disorders. Cancer Genetics and Cytogenetics, 1989, 37, 1-8.	1.0	13
519	Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU. Investigational New Drugs, 1988, 6, 121-124.	2.6	2
520	Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: Three cases and review of the literature. Mycopathologia, 1988, 101, 105-111.	3.1	49
521	Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. American Journal of Medicine, 1988, 84, 233-239.	1.5	124
522	A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 1988, 35, 143-150.	1.0	3

#	ARTICLE	IF	CITATIONS
523	Associations between morphology, karyotype, and clinical features in myeloid leukemias. Human Pathology, 1987, 18, 211-225.	2.0	142
524	High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection. Biomedical Applications, 1987, 420, 81-88.	1.7	26
525	Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1986, 18, 257-60.	2.3	2
526	New high-performance liquid chromatographic assay for plasma doxorubicin. Biomedical Applications, 1985, 337, 194-200.	1.7	18
527	utility of ultrasound in the diagnosis of wandering abdominal viscera. Journal of Clinical Ultrasound, 1985, 13, 275-277.	0.8	5
528	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer, 1985, 56, 443-449.	4.1	68
529	High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. European Journal of Cancer & Clinical Oncology, 1985, 21, 1261-1263.	0.7	3
530	Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy. European Journal of Cancer & Clinical Oncology, 1985, 21, 563-571.	0.7	17
531	Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1984, 12, 125-30.	2.3	56
532	Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. European Journal of Cancer & Clinical Oncology, 1984, 20, 1061-1068.	0.7	12
533	Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. American Journal of Medicine, 1984, 76, 827-841.	1.5	410
534	The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: The role of granulocytes as a helper population. Journal of Allergy and Clinical Immunology, 1984, 74, 280-290.	2.9	0
535	A Morphologic and Cytochemical Study of Acute Myelomonocytic Leukemia with Abnormal Marrow Eosinophils Associated with Inv(16)(p13q22). American Journal of Clinical Pathology, 1984, 81, 733-741.	0.7	67
536	Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B. Cellular Immunology, 1983, 81, 357-372.	3.0	1
537	The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: A 12-year study (1970-1982). Cancer Genetics and Cytogenetics, 1983, 10, 219-236.	1.0	102
538	Association of an Inversion of Chromosome 16 with Abnormal Marrow Eosinophils in Acute Myelomonocytic Leukemia. New England Journal of Medicine, 1983, 309, 630-636.	27.0	508
539	Rates of cholesterol biosynthesis are related to early differentiation in acute non-lymphocytic leukaemia cells. British Journal of Haematology, 1983, 54, 459-466.	2.5	0
540	Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer, 1982, 49, 2222-2225.	4.1	16

#	ARTICLE	IF	CITATIONS
541	Chromosome Changes in Hematologic Malignancies. Ca-A Cancer Journal for Clinicians, 1981, 31, 222-238.	329.8	8
542	Acute Myeloid Leukemia in Adults: Remission Induction Therapy. , 0, , 268-277.		0
543	Acute Myeloid Leukemia in Adults: Postremission Therapy. , 0, , 278-286.		0
544	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Advances, 0, , .	5.2	3